Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: Long-term results of a phase I/II clinical trial

Clinical Lung Cancer

Volumn 6, Issue 5, 2005, Pages 304-309

  Chen, Ming ^a   Chen, Yuan Yuan ^a   Bao, Yong ^a   Xian, Chao Gui ^a   Liu, Guo Zhen ^a   Zhang, Li ^a   Xu, Guang Chuan ^a   Deng, Xiao Wu ^a   Lu, Tai Xiang ^a   Qian, Jian Yang ^a   Cui, Nian Ji ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Esophagitis; Locoregional progression; Neutropenia; Pneumonitis

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; MITOMYCIN; NAVELBINE; PACLITAXEL; VINDESINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG RESPONSE; ESOPHAGITIS; ESOPHAGUS STRICTURE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 20744435324     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2005.n.010     Document Type: Article

References (20)

1. Enstrom JE, Austin DF. Interpreting cancer survival rate. Science 1977; 1:847-851.
2. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. JNCI 1996; 88:1210-1215.
3. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83:417-423.
4. Crino L, Latmi P, Meacci M, et al. Induction chemotherapy plus high dose radiation versus radiation alone in locally advanced non-small cell lung cancer. Ann Oncol 1993; 4:847-851.
5. Sause WT, Scott C, Taylor S, et al. RTOG 88-08 and ECOG 45-88: preliminary results of a randomized trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 1995; 87:198-205.
6. Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer: a meta analysis using update data on individual patients from 52 randomized clinical trials. BMJ 1995; 311:899-909
7. Marino P, Preatoni A, Cantoni A. Randomized trial of radiation therapy alone verse combined chemotherapy and radiotherapy in stages IIIA and IIIB non-small cell lung cancer. Cancer 1995; 76:593-601.
8. Withers HR, Tailor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27:131-146.
9. FU XL, Jiang GL, Wang LJ, et al. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trail. Int J Radiat Oncol Biol Phys 1997; 39:545-552.
10. Saunders MI, Dische S, Barrett A, et al. Randomized multicentre trials of CHART vs. conventional radiotherapy in head and neck and non-small cell lung cancer. Br J Cancer 1996; 73:1455-1462.
11. Shi XH, Yao WQ, Liu TF. Late course accelerated fraction radiation therapy in esophageal carcinoma. Radiother Oncol 1999; 51:21-26.
12. Komaki R, Scott CB, Sause WT, et al. Induction cisplatin/vinblastine and irradiation therapy vs. irradiation therapy in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Int J Radiat Oncol Biol Phys 1997; 39:537-544.
13. Sculier JP, Paesmans M, Lafitte JJ, et al. Randomized phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. Ann Oncol 1999; 10:295-303.
14. Viallet J, Brassard MA, Souham L, et al. A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma. Cancer 1999; 85:2563-2569.
15. Belani CP. Chemotherapy regimens in advanced non-small cell lung cancer: recent randomized trials. Clin Lung Cancer 2000; 2(suppl 1):S7-S10.
16. Cox JD, Azarnia N, Byhardt RW. Hyperfractionated radiation therapy (1.2 Gy bid) with 69.6 Gy total dose increases survival in favorable patients with stage III non-small cell carcinoma of the lung: report of RTOG 83-11. J Clin Oncol 1990; 8:1543-1555.
17. Withers. Biologic basis for fractionation schemes. Cancer 1985; 55(Suppl 9):2086-2095.
18. Curran WJ, Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemoradiation therapy for patients with unresectable stage III non-small cell lung cancer: initial report of RTOG 9410. Proc Am Soc Clin Oncol 2000; 19:484a (Abstract #1891).
19. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycine, vindesin and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999; 17:2692-2699.
20. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21:2004-2010.